Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Genel Energy Reports FY25 Net Loss Below Fears, EBITDAX Beats Forecasts 
Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity 
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
United Airlines Cuts Flights 5% Amid Soaring Fuel Costs From Iran War 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
